We took advantage of the bispecific property of LTTs to engineer a new recombinant drug against solid tumors and focused on a different approach that we proposed would simultaneously target both the tumor with EGF and the tumor vasculature with a high-affinity fragment of urokinase. This evidence concerns the gene EGF and neoplasm.